vs

Side-by-side financial comparison of Beta Bionics, Inc. (BBNX) and FIVE STAR BANCORP (FSBC). Click either name above to swap in a different company.

FIVE STAR BANCORP is the larger business by last-quarter revenue ($45.1M vs $27.6M, roughly 1.6× Beta Bionics, Inc.). FIVE STAR BANCORP runs the higher net margin — 41.3% vs -79.3%, a 120.5% gap on every dollar of revenue.

Beta Bionics, Inc. is a medical technology company focused on developing and commercializing advanced automated diabetes management solutions. Its core product is the iLet Bionic Pancreas, a wearable device that automatically adjusts insulin and glucagon delivery for people with Type 1 and Type 2 diabetes, serving primarily the U.S. healthcare market with plans for global expansion.

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

BBNX vs FSBC — Head-to-Head

Bigger by revenue
FSBC
FSBC
1.6× larger
FSBC
$45.1M
$27.6M
BBNX
Higher net margin
FSBC
FSBC
120.5% more per $
FSBC
41.3%
-79.3%
BBNX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BBNX
BBNX
FSBC
FSBC
Revenue
$27.6M
$45.1M
Net Profit
$-21.9M
$18.6M
Gross Margin
59.5%
Operating Margin
-47.4%
Net Margin
-79.3%
41.3%
Revenue YoY
56.6%
Net Profit YoY
23.6%
42.0%
EPS (diluted)
$-0.49
$0.87

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BBNX
BBNX
FSBC
FSBC
Q1 26
$27.6M
$45.1M
Q4 25
$32.1M
$43.5M
Q3 25
$27.3M
$41.3M
Q2 25
$23.2M
$38.3M
Q1 25
$17.6M
$35.3M
Q4 24
$35.2M
Q3 24
$31.8M
Q2 24
$30.7M
Net Profit
BBNX
BBNX
FSBC
FSBC
Q1 26
$-21.9M
$18.6M
Q4 25
$-13.5M
$17.6M
Q3 25
$-14.2M
$16.3M
Q2 25
$-16.9M
$14.5M
Q1 25
$-28.7M
$13.1M
Q4 24
$13.3M
Q3 24
$10.9M
Q2 24
$10.8M
Gross Margin
BBNX
BBNX
FSBC
FSBC
Q1 26
59.5%
Q4 25
59.0%
Q3 25
55.5%
Q2 25
53.8%
Q1 25
50.9%
Q4 24
Q3 24
Q2 24
Operating Margin
BBNX
BBNX
FSBC
FSBC
Q1 26
-47.4%
Q4 25
-50.2%
52.9%
Q3 25
-62.5%
53.8%
Q2 25
-85.5%
52.4%
Q1 25
-105.7%
52.0%
Q4 24
55.1%
Q3 24
48.0%
Q2 24
49.4%
Net Margin
BBNX
BBNX
FSBC
FSBC
Q1 26
-79.3%
41.3%
Q4 25
-41.9%
40.6%
Q3 25
-52.1%
39.6%
Q2 25
-72.6%
37.9%
Q1 25
-162.5%
37.1%
Q4 24
37.9%
Q3 24
34.4%
Q2 24
35.2%
EPS (diluted)
BBNX
BBNX
FSBC
FSBC
Q1 26
$-0.49
$0.87
Q4 25
$-0.16
$0.83
Q3 25
$-0.33
$0.77
Q2 25
$-0.39
$0.68
Q1 25
$-0.93
$0.62
Q4 24
$0.61
Q3 24
$0.52
Q2 24
$0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BBNX
BBNX
FSBC
FSBC
Cash + ST InvestmentsLiquidity on hand
$199.5M
$644.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$271.2M
$458.5M
Total Assets
$304.4M
$5.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BBNX
BBNX
FSBC
FSBC
Q1 26
$199.5M
$644.4M
Q4 25
$219.1M
Q3 25
$228.7M
Q2 25
$249.7M
Q1 25
$231.5M
Q4 24
Q3 24
Q2 24
Stockholders' Equity
BBNX
BBNX
FSBC
FSBC
Q1 26
$271.2M
$458.5M
Q4 25
$287.6M
$445.8M
Q3 25
$294.8M
$431.3M
Q2 25
$301.6M
$416.7M
Q1 25
$313.8M
$406.5M
Q4 24
$396.6M
Q3 24
$389.9M
Q2 24
$380.5M
Total Assets
BBNX
BBNX
FSBC
FSBC
Q1 26
$304.4M
$5.0B
Q4 25
$328.7M
$4.8B
Q3 25
$330.0M
$4.6B
Q2 25
$330.0M
$4.4B
Q1 25
$338.0M
$4.2B
Q4 24
$4.1B
Q3 24
$3.9B
Q2 24
$3.6B

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BBNX
BBNX

Segment breakdown not available.

FSBC
FSBC

Net Interest Income$43.5M96%
Noninterest Income$1.6M4%

Related Comparisons